



Andy Beshear
GOVERNOR

CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES

Eric Friedlander
SECRETARY

Justin Dearing
ACTING DIRECTOR

275 East Main Street, 6-WA
Frankfort, Kentucky 406 21
chfs.ky.gov

Lisa Lee
COMMISSIONER

PROVIDER LETTER

TO: Hospitals (PT 01 / PL #A-267)
Preventive & Remedial Public Health Services (PT 20 / PL #A-24)
Primary Care Center-Federally Qualified Health Centers (PT 31 / PL #A-393)
Rural Health Clinic (PT 35 / PL #A-233)
Renal Dialysis Clinic (PT 39 / PL #A-28)
Physician (PT 64 / PL #A-393)
Physician Group (PT 65 / PL #A-48)
Nurse Midwife (PT 72 / PL #7)
Birthing Center (PT 73 / PL #A-2)
Certified Registered Nurse Anesthetist (CRNA) (PL 74 / PL #A-37)
Certified Registered Nurse Anesthetist (CRNA) Group (PL 749 / PL #A-1)
Advanced Practice Registered Nurse (APRN) (PT 78 / PL #A-110)
Advanced Practice Registered Nurse (APRN) Group (PT 789 / PL #A-8)
Physician Assistant (PT 95 / PL #A-105)
Physician Assistant Group (PT 959 / PL #A3)

DATE: October 16, 2023

RE: RSV Vaccine Updates

The Kentucky Department for Medicaid Services is informing providers of the changes listed below.

- The following codes have been updated on the Physician's and Preventative Fee Schedules:
 - 90683 RSV, Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use.
Eff: 01/01/24
 - 90378 RSV, Respiratory Syncytial Virus, Synagis (palivizumab) "Monoclonal Antibody" 50mg, for injection into tissue or muscle.
Eff: 10/1/2023

- 90380 RSV, Respiratory Syncytial Virus, AstraZeneca/Sobi/Sanofi's Beyfortus (nirsevimab-alip) "Monoclonal Antibody" seasonal dose, 0.5ml, for intramuscular use.
Eff: 10/1/2023
- 90381 RSV, Respiratory Syncytial Virus, AstraZeneca/Sobi/Sanofi's Beyfortus (nirsevimab-alip) "Monoclonal Antibody" seasonal dose, 1.0 ml, for intramuscular use.
Eff: 10/1/2023
- 90678 RSV, Respiratory Syncytial Virus, Pfizer's Abrysvo "Vaccine" prefusionF, subunit, bivalent, recombinant, for intramuscular use.
Eff: 10/1/2023
- 90679 RSV, Respiratory Syncytial Virus, GlaxoSmithKline's Arexvy "Vaccine" adjuvanted, for intramuscular use.
Eff: 10/1/2023

Sincerely,

Justin Dearing

Electronically signed by:
Justin Dearing, Acting Director
Division of Health Care Policy
Department for Medicaid Services

JD/cts/kl